clinical trial · NCT07124078
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Chronic Graft-versus-host-diseaseINCA034176Best available Treatment (BAT)
brief summary
This study will be conducted to compare Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
started
May 31, 2026
primary completion
Jan 31, 2029
completion
Jul 31, 2029
last updated
Apr 14, 2026
official title
A Phase 2, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol